NYSE:ZYME

Zymeworks Stock Insider Trading

Healthcare > Biotechnology

Buy ZYME

*Your capital is at risk

$24.35

+0.240 (+1.00%)

At Close: Jun 03, 2026

Zymeworks Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 51.85. In total, the insiders bought 4.91M and sold 187.93K ZYME shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	51.85
● Buy	4.91M shares
● Sell	187.93K shares
90% Buy Activity Strong Negative Correlation
Sell Signal Low Confidence Jan 12, 2026 Analysis Breakdown: Signal is highly questionable due to a strongly contradictory positive Insider Power Score of 51.85. Partially supported by a negative historical correlation. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Jan 12, 2026 Buy	Common Stock M-Exempt	Smith Jeffrey T L EVP & Chief Medical Officer	Officer	17 666 Value: $409.1K
Jan 12, 2026 Buy	Stock Option (Right to Buy) A-Award	Campoy Carlos Director	Director	11 500 Value: $266.3K
Jan 12, 2026 Buy	Restricted Stock Unit A-Award	Campoy Carlos Director	Director	7 700 Value: $178.3K
Jan 12, 2026 Buy	Stock Option (Right to Buy) A-Award	Mahony Susan Director	Director	11 500 Value: $266.3K
Jan 12, 2026 Buy	Performance Stock Unit A-Award	Moore Paul Andrew Chief Scientific Officer	Officer	66 000 Value: $1.53M
Jan 12, 2026 Buy	Common Stock M-Exempt	Moore Paul Andrew Chief Scientific Officer	Officer	17 666 Value: $409.1K
Jan 12, 2026 Buy	Restricted Stock Unit M-Exempt	Moore Paul Andrew Chief Scientific Officer	Officer	17 666 Value: $409.1K
Jan 12, 2026 Buy	Common Stock M-Exempt	Galbraith Kenneth Chair & CEO	CEO / President	64 000 Value: $1.48M
Jan 12, 2026 Buy	Restricted Stock Unit A-Award	Galbraith Kenneth Chair & CEO	CEO / President	144 000 Value: $3.34M
Jan 12, 2026 Buy	Restricted Stock Unit M-Exempt	Galbraith Kenneth Chair & CEO	CEO / President	64 000 Value: $1.48M
Jan 09, 2026 Buy	Stock Option (Right to Buy)	Hollywood Mark EVP & Chief Operating Officer	C-Suite Officer	61 000 Value: $488.0K
Jan 09, 2026 Buy	Stock Option (Right to Buy)	Hollywood Mark EVP & Chief Operating Officer	C-Suite Officer	90 000 Value: $630.0K
Jan 09, 2026 Buy	Stock Option (Right to Buy)	Hollywood Mark EVP & Chief Operating Officer	C-Suite Officer	30 000 Value: $1.04M
Jan 09, 2026 Buy	Common Stock	Hollywood Mark EVP & Chief Operating Officer	C-Suite Officer	0 Value: $0
Jan 09, 2026 Buy	Restricted Stock Unit	Hollywood Mark EVP & Chief Operating Officer	C-Suite Officer	53 000 Value: $1.23M
Jan 09, 2026 Buy	Stock Option (Right to Buy)	Hollywood Mark EVP & Chief Operating Officer	C-Suite Officer	24 375 Value: $858.0K
Jan 09, 2026 Buy	Stock Option (Right to Buy)	Hollywood Mark EVP & Chief Operating Officer	C-Suite Officer	80 000 Value: $1.22M
Jan 09, 2026 Buy	Stock Option (Right to Buy)	Hollywood Mark EVP & Chief Operating Officer	C-Suite Officer	90 000 Value: $950.4K
Jan 09, 2026 Buy	Stock Option (Right to Buy)	Hollywood Mark EVP & Chief Operating Officer	C-Suite Officer	79 000 Value: $1.04M
Jan 06, 2026 Buy	Common Stock A-Award	Patterson Leone D EVP, Chief Bus & Fin Officer	Officer	459 Value: $5K
Jan 05, 2026 Sell	Common Stock S-Sale	Galbraith Kenneth Chair & CEO	CEO / President	31 686 Value: $795.2K
Jan 05, 2026 Buy	Common Stock M-Exempt	Galbraith Kenneth Chair & CEO	CEO / President	66 666 Value: $1.70M
Jan 05, 2026 Sell	Common Stock S-Sale	Smith Jeffrey T L EVP & Chief Medical Officer	Officer	10 538 Value: $264.5K
Jan 05, 2026 Buy	Restricted Stock Unit M-Exempt	Smith Jeffrey T L EVP & Chief Medical Officer	Officer	20 000 Value: $509.6K
Jan 05, 2026 Buy	Common Stock M-Exempt	Smith Jeffrey T L EVP & Chief Medical Officer	Officer	20 000 Value: $509.6K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT ZYMEWORKS INC

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and colorectal cancer; and ZW49, a biparatopic anti-human epidermal growth factor receptor 2 ...

Read Full Profile Here